Terence Flynn, Biotech Analyst at Morgan Stanley, discusses Eli Lilly's recent stock boost and its designation as Morgan Stanley's top pick for 2025. He highlights the robust growth potential of Eli ...
BioSpace recaps 2024’s top venture capital rounds in biopharma, from Xaira Therapeutics’ blockbuster $1B raise to ...
A breathtaking 30-foot centerpiece tree takes center stage in the Eli Lilly Hall. Each of the trees ... enjoy live performances of classic holiday songs. For something a little more interactive ...
The activation marked the latest phase of the ongoing It Takes 2 campaign from Boehringer Ingelheim and Eli Lilly.
California is not one of those states. Newsom in October rejected a $35 monthly insulin copay cap. In his veto message, he cited the state’s $100 million investment in insulin production as an example ...
The Golden Globes have a reputation for being Hollywood’s least serious awards show, allowing us all to revel in the mess.
The drugmaker launched a campaign supporting its weight loss medication Contrave, all backed by a cover version of Lesley Gore’s 1963 hit “You Don’t Own Me.” ...
Eli Lilly ( LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 ...
Heading into fiscal 2025, CEO David Ricks said the company expects sales of weight-loss drugs will continue growing, and noted that it expects "to produce at least 60% more salable doses" of the drugs ...
Eli Lilly's GLP-1 market dominance, supported by superior efficacy and strong manufacturing investments, positions it as a leader alongside Novo Nordisk, with forecasted revenue growth to $75B by ...
Eli Lilly cut its outlook for fourth-quarter revenue citing sluggish growth in the market for incretin, which increases ...